Nova Law, MD
Family Medicine · Birmingham, ALNPI 1043230212
Payments from drug & device makers
What this record shows
Eli Lilly accounts for 67.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $2,034 and has fallen 63.6% since, to $741 in 2025.
Across 66 payments — averaging $52.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Lilly USA, LLC$531
- Novo Nordisk$195
- Kowa Pharmaceuticals America, Inc.$183
- Redhill Biopharma Inc.$66
- AbbVie$55
- plus $89 from 5 others
Across 20 payments — averaging $40,443 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$539K
- Orasure Technologies Inc.$107K
- BD$105K
- Roche Molecular Systems, Inc.$44K
- Sekisui Diagnostics LLC$13K
What the payments were for
- Travel & lodging$2,05359%
- Food & beverage$1,43441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 17 | $2,369 |
| Lilly USA, LLC | 17 | $531 |
| Novo Nordisk | 11 | $195 |
| Kowa Pharmaceuticals America, Inc. | 8 | $183 |
| Redhill Biopharma Inc. | 4 | $66 |
| AbbVie(2 entities) | 4 | $55 |
| Shield Therapeutics Inc | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,487 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $145,083 |
| MounjaroTirzepatide | 39 | $41,124 |
| JardianceEmpagliflozin | 23 | $22,360 |
| EliquisApixaban | 20 | $20,602 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 51 | $13,417 |
| TrulicityDulaglutide | 12 | $10,977 |
| FarxigaDapagliflozin Propanediol | 18 | $10,897 |
| TradjentaLinagliptin | 20 | $10,810 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $10,657 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $9,158 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,017 |
| ValacyclovirValacyclovir Hcl | 27 | $2,369 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 53 | $1,565 |
| Atorvastatin Calcium | 88 | $1,253 |
| Pravastatin Sodium | 42 | $1,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $195 | $145,083123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $531 | $52,10151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Birmingham
- Lashelle BarmoreBirmingham$486K
- Scott WeisbergBirmingham$38K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.